| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.6 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.6 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |